AUTHOR=Fang Xinyi , Wu Haoran , Wang Xinmiao , Lian Fengmei , Li Min , Miao Runyu , Wei Jiahua , Tian Jiaxing 

TITLE=Modulation of Gut Microbiota and Metabolites by Berberine in Treating Mice With Disturbances in Glucose and Lipid Metabolism

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.870407

DOI=10.3389/fphar.2022.870407

ISSN=1663-9812

ABSTRACT=<p><bold>Introduction:</bold> Glucose and lipid metabolism disturbances has become the third major disease after cancer and cardio-cerebrovascular diseases. Emerging evidence shows that berberine can effectively intervene glucose and lipid metabolism disturbances, but the underlying mechanisms of this remain unclear. To investigate this issue, we performed metagenomic and metabolomic analysis in a group of normal mice (the NC group), mice with disturbances in glucose and lipid metabolism (the MC group) and mice with disturbances in glucose and lipid metabolism after berberine intervention (the BER group).</p><p><bold>Result:</bold> Firstly, analysis of the clinical indicators revealed that berberine significantly improved the blood glucose and blood lipid of the host. The fasting blood glucose level decreased by approximately 30% in the BER group after 8 weeks and the oral glucose tolerance test showed that the blood glucose level of the BER group was lower than that of the MC group at any time. Besides, berberine significantly reduced body weight, total plasma cholesterol and triglyceride. Secondly, compared to the NC group, we found dramatically decreased microbial richness and diversity in the MC group and BER group. Thirdly, LDA effect size suggested that berberine significantly altered the overall gut microbiota structure and enriched many bacteria, including <italic>Akkermansia</italic> (<italic>p</italic> &lt; 0.01), <italic>Eubacterium</italic> (<italic>p</italic> &lt; 0.01) and <italic>Ruminococcus</italic> (<italic>p</italic> &lt; 0.01). Fourthly, the metabolomic analysis suggested that there were significant differences in the metabolomics signature of each group. For example, isoleucine (<italic>p</italic> &lt; 0.01), phenylalanine (<italic>p</italic> &lt; 0.05), and arbutin (<italic>p</italic> &lt; 0.05) significantly increased in the MC group, and berberine intervention significantly reduced them. The arbutin content in the BER group was even lower than that in the NC group. Fifthly, by combined analysis of metagenomics and metabolomics, we observed that there were significantly negative correlations between the reduced faecal metabolites (e.g., arbutin) in the BER group and the enriched gut microbiota (e.g., <italic>Eubacterium</italic> and <italic>Ruminococcus</italic>) (<italic>p</italic> &lt; 0.05)<italic>.</italic> Finally, the correlation analysis between gut microbiota and clinical indices indicated that the bacteria (e.g., <italic>Eubacterium</italic>) enriched in the BER group were negatively associated with the above-mentioned clinical indices (<italic>p</italic> &lt; 0.05).</p><p><bold>Conclusion:</bold> Overall, our results describe that the changes of gut microbiota and metabolites are associated with berberine improving glucose and lipid metabolism disturbances.</p>